|

The VALVE-AI Trial

RECRUITINGN/ASponsored by National Defense Medical Center, Taiwan
Actively Recruiting
PhaseN/A
SponsorNational Defense Medical Center, Taiwan
Started2025-07-01
Est. completion2026-07-01
Eligibility
Age60 Years – 85 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT07023510

Summary

The goal of this clinical trial is to learn if an artificial intelligence-powered electrocardiogram (AI-ECG) can help detect moderate or severe valvular heart diseases (VHD) in adults. The main question it aims to answer is: ．Can AI-ECG screening identify patients with significant heart valve diseases who may benefit from early echocardiography? Researchers will compare the rate of moderate or severe VHD detection between the experimental group and the control group to see if AI-ECG improve the detection rate of significant VHD. Participants will: * Be classified as high- or low-risk for VHD using an AI-ECG system * In the experimental group, high-risk participants will receive echocardiography based on AI-ECG results * In the control group, usual clinical care will be provided without routine echocardiography for AI-ECG high-risk results.

Eligibility

Age: 60 Years – 85 YearsHealthy volunteers accepted
Inclusion Criteria:

* At least one 12-lead ECG within 1 year
* Age 60-85 years of age

Exclusion Criteria:

* Documented echocardiography within 3 years before indexed ECG
* Any known valvular heart disease
* History of any valvular surgery
* Post-heart transplant

Conditions2

Heart DiseaseValvular Heart Disease Patients

Browse More Trials

Heart Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.